Compare L3Harris Technologies Inc (LHX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs ResMed Inc. — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and ResMed Inc. for 51 Days on average.
| LHX | RMD | |
|---|---|---|
Market Cap | $44.12B | $31.89B |
Volume | 1,202,852 | 618,314 |
Sector | Industrials | Health |
52-Week High | $378.48 | $277.88 |
52-Week Low | $233.63 | $182.82 |
Typical Hold Time | 56 Days | 51 Days |
Enterprise Value | $54.56B | $31.24B |
Dividend Yield | 2.11% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.
LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
